New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
07:17 EDTHZNPHorizon Pharma price target raised to $25 from $18 at Stifel
Stifel increased its price target on Horizon as the firm thinks that the company's acquisition of Vidara has left it in "ideal position" to become profitable and meet its revenue and EBITDA guidance. The firm thinks the company's drug portfolio is poised to perform well, and keeps a Buy rating on the shares.
News For HZNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
07:03 EDTHZNPHorizon Pharma announces USPTO issuance of Notice of Allowance
Subscribe for More Information
June 26, 2015
07:28 EDTHZNPHorizon Pharma price target raised to $40 from $32 at UBS
Subscribe for More Information
June 23, 2015
07:36 EDTHZNPJMP Securities to hold a conference
Subscribe for More Information
07:12 EDTHZNPHorizon Pharma announces notice of allowance with claims covering Ravicti
Horizon Pharma announced that it has received from the United States Patent and Trademark Office a Notice of Allowance for U.S. patent application number 13/775,000, entitled "Methods of Therapeutic Monitoring of Nitrogen Scavenging Drugs" that covers Horizon's U.S. approved product Ravicti Oral Liquid.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use